13F filer · CIK 315066 ↗
Fidelity Investments
You are looking at Q3 2022. See the latest, Q2 2026 →
Reported value
$958.93B
−4.4% on the quarter before
Positions
5,305
381 new · 427 sold out
Top 10
26.0%
of the value
Est. gain
−$37.37B
on stocks held all quarter
Est. return
−3.9%
on those stocks since Q2 2022
Positions as of Sep 30, 2022, from Fidelity Investments's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
The 24 largest positions, 36% of the reported value, each sized by its share, colored by what the fund did with it since Q2 2022. Striped tiles are options.
Largest buys
Since Q2 2022, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Amazon~$1.81BAdded · 3.0% → 3.6%+16,008,843 shares
- Apple~$909.7MAdded · 4.7% → 5.1%+6,582,142 shares
- Tesla~$774.7MAdded · 0.8% → 1.1%+2,920,476 shares
- Snap~$767.7MAdded · 0.1% → 0.1%+78,175,255 shares
- Uber~$752.2MAdded · 0.2% → 0.3%+28,386,061 shares
- Netflix~$745.9MAdded · 0.3% → 0.5%+3,168,047 shares
- Cigna Corp New~$524.9MAdded · 0.4% → 0.5%+1,891,571 shares
- Thermo Fisher Scientific Inc~$500.9MAdded · 0.5% → 0.6%+987,695 shares
- Molina Healthcare~$494.1MAdded · 0.0% → 0.1%+1,497,997 shares
- Autodesk~$446.5MAdded · 0.1% → 0.1%+2,390,079 shares
Largest sells
Since Q2 2022, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Salesforce~$859.4MCut · 0.8% → 0.6%−5,974,352 shares
- Gsk Plc~$766.2MSold out · 0.1% → 0.0%−17,601,698 shares
- Microsoft~$725.1MCut · 5.3% → 5.0%−3,113,246 shares
- Canadian Nat Res Ltd~$681.3MCut · 0.4% → 0.3%−14,636,848 shares
- Lauder Estee Cos Inc~$665.4MCut · 0.2% → 0.1%−3,082,081 shares
- Horizon Therapeutics Pub L~$642.7MCut · 0.1% → 0.0%−10,385,065 shares
- Pioneer Nat Res Co~$618.7MCut · 0.2% → 0.2%−2,857,469 shares
- Newmont Corp~$580.3MCut · 0.2% → 0.1%−13,806,080 shares
- Freeport-McMoRan~$563.7MCut · 0.3% → 0.3%−20,624,445 shares
- Chemocentryx Inc~$551.6MCut · 0.0% → 0.0%−10,671,158 shares
Holdings
As of Sep 30, 2022. Changes are in shares against Jun 30, 2022, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| AppleCOM · shares +1.9% · price +1.1% | 5.1% | $48.49B | +$509.6M | ||||||||
| MicrosoftCOM · shares −1.5% · price −9.3% | 5.0% | $47.53B | −$4.88B | ||||||||
| AmazonCOM · shares +5.6% · price +6.4% | 3.6% | $34.13B | +$1.94B | ||||||||
| Unitedhealth Group IncCOM · shares +1.1% · price −1.7% | 2.7% | $25.45B | −$427.9M | ||||||||
| AlphabetCAP STK CL A · shares +0.4% · price −12.2% | 2.4% | $22.98B | −$3.19B | ||||||||
| NvidiaCOM · shares −0.7% · price −19.9% | 1.8% | $16.95B | −$4.22B | ||||||||
| MetaCL A · shares −0.4% · price −15.9% | 1.6% | $15.64B | −$2.95B | ||||||||
| AlphabetCAP STK CL C · shares −2.4% · price −12.1% | 1.4% | $13.21B | −$1.82B | ||||||||
| Berkshire Hathaway Inc DelCL A · shares +0.3% · price −0.6% | 1.3% | $12.94B | −$78.7M | ||||||||
| Exxon Mobil CorpCOM · shares +3.7% · price +2.0% | 1.3% | $12.24B | +$225.7M | ||||||||
| Eli LillyCOM · shares +1.9% · price −0.3% | 1.1% | $10.69B | −$28.5M | ||||||||
| TeslaCOM · shares +8.2% · price +18.2% | 1.1% | $10.19B | +$1.45B | ||||||||
| Visa Inc.COM CL A · shares −1.2% · price −9.8% | 0.89% | $8.53B | −$923.4M | ||||||||
| Regeneron PharmaceuticalsCOM · shares +6.2% · price +16.5% | 0.78% | $7.45B | +$994.6M | ||||||||
| Wells Fargo Co NewCOM · shares +0.2% · price +2.7% | 0.75% | $7.21B | +$187.8M | ||||||||
| Bk Of America CorpCOM · shares +2.6% · price −3.0% | 0.73% | $6.98B | −$209.5M | ||||||||
| MastercardCL A · shares −1.1% · price −9.9% | 0.71% | $6.78B | −$743.1M | ||||||||
| Danaher CorporationCOM · shares +1.1% · price +1.9% | 0.69% | $6.66B | +$121.7M | ||||||||
| SalesforceCOM · shares −12% · price −12.8% | 0.65% | $6.19B | −$911.7M | ||||||||
| Thermo Fisher Scientific IncCOM · shares +9.9% · price −6.6% | 0.58% | $5.56B | −$360.3M | ||||||||
| Marvell Technology IncCOM · shares +2.4% · price −1.4% | 0.57% | $5.49B | −$77.4M | ||||||||
| Coca Cola CoCOM · shares −4.5% · price −11.0% | 0.56% | $5.33B | −$655.7M | ||||||||
| Lululemon Athletica IncCOM · shares −0.4% · price +2.5% | 0.53% | $5.13B | +$127.5M | ||||||||
| Vertex Pharmaceuticals IncCOM · shares +3.7% · price +2.8% | 0.52% | $5.03B | +$129.8M | ||||||||
| Hess CorpCOM · shares −1.6% · price +2.9% | 0.52% | $5.01B | +$140.1M | ||||||||
| Total · 5,305 positions | 100% | $958.93B | −$37.37B |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q2 2022 to Q3 2022: 4,364 stocks held throughout, down $37.37B (−3.9%).
- Amazon+$1.94B+6%
- Tesla3:1 split+$1.45B+18%
- Netflix+$1.02B+35%
- Regeneron Pharmaceuticals+$994.6M+17%
- Alnylam Pharmaceuticals Inc+$703.3M+37%
- Alphabet20:1 split−$1.82B−12%
- Meta−$2.95B−16%
- Alphabet20:1 split−$3.19B−12%
- Nvidia−$4.22B−20%
- Microsoft−$4.88B−9%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out, 31 splits read into the share counts.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 13, 2026 | $2.30T+21% | SEC ↗ |
| Q1 2026 | May 15, 2026 | $1.90T−3% | SEC ↗ |
| Q4 2025 | Feb 17, 2026 | $1.96T+2% | SEC ↗ |
| Q3 2025 | Nov 13, 2025 | $1.92T+8% | SEC ↗ |
| Q2 2025 | Aug 14, 2025 | $1.77T+13% | SEC ↗ |
| Q1 2025 | May 12, 2025 | $1.57T−7% | SEC ↗ |
| Q4 2024 | Feb 13, 2025 | $1.68T+2% | SEC ↗ |
| Q3 2024 | Nov 13, 2024 | $1.64T+5% | SEC ↗ |
| Q2 2024 | Aug 13, 2024 | $1.56T+5% | SEC ↗ |
| Q1 2024 | May 13, 2024 | $1.49T+14% | SEC ↗ |
| Q4 2023 | Feb 13, 2024 | $1.30T+13% | SEC ↗ |
| Q3 2023 | Nov 13, 2023 | $1.16T−3% | SEC ↗ |
| Q2 2023 | Aug 11, 2023 | $1.19T−45% | SEC ↗ |
| Q1 2023 | May 11, 2023 (amended) | $2.19T+117% | SEC ↗ |
| Q4 2022 | Feb 13, 2023 | $1.01T+5% | SEC ↗ |
| Q3 2022 | Nov 10, 2022 | $958.93B−4% | SEC ↗ |
| Q2 2022 | Aug 12, 2022 | $1.00T−20% | SEC ↗ |
| Q1 2022 | May 13, 2022 | $1.25T−8% | SEC ↗ |
| Q4 2021 | Feb 14, 2022 | $1.35T+7% | SEC ↗ |
| Q3 2021 | Feb 14, 2022 (amended) | $1.26T−1% | SEC ↗ |
| Q2 2021 | Aug 13, 2021 | $1.28T+9% | SEC ↗ |
| Q1 2021 | May 14, 2021 | $1.17T+4% | SEC ↗ |
| Q4 2020 | Feb 8, 2021 | $1.12T+14% | SEC ↗ |
| Q3 2020 | Nov 13, 2020 | $989.33B+9% | SEC ↗ |
| Q2 2020 | Aug 24, 2020 (amended) | $909.48B+26% | SEC ↗ |
| Q1 2020 | May 14, 2020 | $722.13B−20% | SEC ↗ |
| Q4 2019 | Feb 7, 2020 | $906.40B+9% | SEC ↗ |
| Q3 2019 | Nov 13, 2019 | $833.77B−3% | SEC ↗ |
| Q2 2019 | Aug 13, 2019 | $856.19B+3% | SEC ↗ |
| Q1 2019 | May 13, 2019 (amended) | $834.93B+14% | SEC ↗ |
| Q4 2018 | Feb 13, 2019 (amended) | $730.25B−18% | SEC ↗ |
| Q3 2018 | Nov 9, 2018 | $888.88B+2% | SEC ↗ |
| Q2 2018 | Aug 10, 2018 (amended) | $868.68B+3% | SEC ↗ |
| Q1 2018 | May 14, 2018 | $842.35B−1% | SEC ↗ |
| Q4 2017 | Feb 12, 2018 | $853.06B+3% | SEC ↗ |
| Q3 2017 | Nov 13, 2017 | $827.12B+3% | SEC ↗ |
| Q2 2017 | Aug 29, 2017 (amended) | $804.55B+2% | SEC ↗ |
| Q1 2017 | May 11, 2017 | $787.10B+5% | SEC ↗ |
| Q4 2016 | Feb 10, 2017 (amended) | $748.25B−0% | SEC ↗ |
| Q3 2016 | Nov 14, 2016 | $750.86B+2% | SEC ↗ |
| Q2 2016 | Aug 11, 2016 | $732.58B+1% | SEC ↗ |
| Q1 2016 | May 16, 2016 | $722.80B | SEC ↗ |